

**Other information
to the quarterly report of
Mabion S.A.
for the first quarter of 2018**

Konstantynów Łódzki, 30 May 2018

A large, light gray geometric network pattern of interconnected lines and dots, resembling a molecular or network structure, is positioned in the bottom right corner of the page.

Other information to the quarterly report of Mabion S.A. for the first quarter of 2018

Contents

1	Selected financial data	3
2	Information about Mabion S.A.	3
2.1	Changes in the organizational structure of the Company's Group	3
2.2	The Company's achievements and failures in the first quarter of 2018 and after the balance-sheet date.	4
2.3	Indication of factors and events, including those of atypical nature, with a significant impact on the condensed financial statements	6
2.4	Position of the Management Board concerning the possibility of meeting the previously published forecasts of results	6
2.5	Structure of share capital	6
2.6	Shareholding structure	8
2.7	The Company's bodies	9
2.7.1	Management Board	9
2.7.2	Supervisory Board	9
2.8	Shares in the Company held by managers and supervisors	9
2.9	Litigation pending before the court, the appropriate arbitration body or the public administration body	11
2.10	Transactions with related parties	11
2.11	Sureties and guarantees granted	11
2.12	Factors which will have an impact on the achieved financial results in the perspective of at least the following quarter	11
2.13	Other information material to the assessment of the Company's position	11
3	Contact details	11

1 Selected financial data

The selected balance sheet items presented in EUR were converted at the average EUR exchange rate published by the National Bank of Poland as at 31 March 2018 (PLN 4.2085 /EUR 1) and as at 31 December 2017 (PLN 4.1709/EUR 1). The selected of the income statement and the cash flow statement were converted into EUR at the arithmetical average of the EUR exchange rates published by the National Bank of Poland prevailing as at the last day of each month during the 9 months ended 31 March 2018 and the 3 months ended 31 March 2017 (PLN 4.1784 /EUR 1 and PLN 4.2891 /EUR 1, respectively).

SELECTED FINANCIAL DATA	in PLN thousand		in EUR thousand	
	from 01.01.2018 to 31.03.2018	from 01.01.2017 to 31.03.2017	from 01.01.2018 to 31.03.2018	from 01.01.2017 to 31.03.2017
Net sales of finished goods, goods for resale and materials	0,	0,	0,	0,
Operating profit (loss)	-14,067	-14,419	-3,367	-3,362
Profit (loss) before tax	-14,349	-12,851	-3,434	-2,996
Net profit (loss)	-14,349	-12,851	-3,434	-2,996
Net cash flows from operating activities	-18,804	-12,106	-4,500	-2,822
Net cash flows from investing activities	-726	-1,906	-174	-444
Net cash flows from financing activities	191,830	12,203	45,910	2,845
Total net cash flows	172,300	-1,809	41,236	-422
	31.03.2018	31.12.2017	31.03.2018	31.12.2017
Total assets	261,202	82,445	62,065	19,767
Liabilities and provisions for liabilities	329,709	136,603	78,344	32,751
Long-term liabilities	15,738	16,233	3,740	3,892
Current liabilities	313,971	120,370	74,604	28,859
Equity	-68,507	-54,158	-16,278	-12,985
Share capital	1,180	1,180	280	283
Number of shares (in pcs)	11,800,000	11,800,000	11,800,000	11,800,000
Net profit (loss) per ordinary share	22.14	7.06	5.26	1.69

2 Information about Mabion S.A.

2.1 Changes in the organizational structure of the Company's Group

Mabion S.A. ("Company", "Issuer", "Mabion") does not have any subsidiaries and does not form a Group.

2.2 The Company's achievements and failures in the first quarter of 2018 and after the balance-sheet date.

On 5 January 2018, the Company's Management Board received information on the initial results of the assessment of the results of the clinical trial conducted in patients treated with MabionCD20 in the indication of non-Hodgkin's lymphomas (NHL) in respect of two primary pharmacokinetic endpoints, from the external company contracted to perform the assessment. The initial results indicated that the assumed bioequivalence criteria were met. This information was published in Current Report No. 2/2018 on 5 January 2018.

On 10 January 2018, the Management Board received initially processed data on the effectiveness of treatment and the overall safety profile of MabionCD20 in the indication of non-Hodgkin's lymphomas (NHL) from an external company (secondary endpoints). Based on the data relating to the efficacy of the therapy, the Management Board assessed the patients' response to treatment in both groups (treated with MabionCD20 and with MabThera) as comparable. In the Company's opinion, MabionCD20 met the requirements of the overall safety profile. The Management Board emphasized that due to the relatively small population of patients participating in the trial compared with the MabionCD20 RA trial, the assessment had not been based on statistical inference. The assessment was based on descriptive statistics. This means that the final assessment of the reported results will be made by the European Medicines Agency (EMA) and may differ from the Company's assessment. Research reports in their final versions will be used in the marketing authorization application (MAA) which the Company is planning to file with the EMA. This information was published in Current Report No. 3/2018 on 10 January 2018.

4 On 11 January 2018, the Company's Management Board obtained information that the last visit of the last patient in the follow-up extension study (the so-called long-term follow-up) of patients included in the MabionCD20 NHL trial had taken place. In conclusion, all the patients who participated in the MabionCD20 NHL trial ended a 46-week treatment and follow-up cycle consisting of the basic treatment and the follow-up period which lasted 26 weeks and additional 20 weeks of long-term follow-up. Therefore, the data collection for all endpoints of the research ended. Based on the collected data the Company is to obtain results in respect of the secondary endpoints related to long-term follow-up. This information was published in Current Report No. 4/2018 on 11 January 2018.

On 15 January 2018, the Management Board received initially processed data in respect of the pharmacokinetic secondary endpoints and pharmacodynamics of MabionCD20 in the indication of non-Hodgkin's lymphomas (NHL) from an external company (secondary endpoints). The Management Board assessed the obtained pharmacokinetic parameters in the groups treated with MabionCD20 and MabThera as equivalent. In respect of the pharmacodynamics, in both groups a depletion (removal) of B-cells was noted, the degree of repletion (recreation) of lymphocytes in both groups was similar. The Management Board emphasized that due to the relatively small population of patients participating in the trial compared with the MabionCD20 RA trial, the assessment had not been based on a simplified statistical approach. This means that the final assessment of the reported results will be made by the European Medicines Agency (EMA) and may differ from the Company's assessment. Trial reports in their final versions will be used in the marketing authorization application (MAA) which the Company is planning to file with the EMA. This information was published in Current Report No. 6/2018 on 15 January 2018.

On 22 March 2018, the Company obtained financing in the amount of PLN 174.8 million, in the form of a borrowing agreement, from the Company's shareholder, i.e. Twiti Investments Ltd. (the Shareholder). The funds for the borrowing were obtained by the Shareholder from the sale of the Company's 1,920,772 ordinary bearer shares under the private offering referred to below. Originally, the borrowing from the Shareholder was to be repaid by 30 June 2018 by way of a set-off between reciprocal claims: The Company's receivables from the Shareholder's payment for the same number of the Company's newly issued ordinary bearer shares as the number shares sold under private offering that were to be issued by the Company at the same price as the price obtained from the sale of shares under private offering, and the Shareholder's receivables from the repayment of the borrowing from the Shareholder. Finally the borrowing was repaid by the Company in cash on 23 April 2018. This information was published in Current Report No. 26/2018 on 23 April 2018.

On 22 March 2018, Twiti Investments Ltd. concluded the agreement concerning the sale of the Company's 1,920,772 ordinary bearer shares in its possession under private offering to a limited number of selected institutional investors, including from the U.S., pursuant to the exception concerning private placements provided for in Section 4(a)(2) of the U.S. Securities Act of

1933, as amended, and non-U.S. investors based on the exclusion provided for in Regulation S of the U.S. Securities Act. The private offering was carried out in a manner which does not constitute a public offering in the meaning of Article 3 par. 1 of the Act of 29 July 2005 on Public Offering (...) and does not require the preparation or approval of the issue prospectus or information memorandum. The sale of shares took place as block trade transactions at the GPW carried out on 23 March 2018 and settled on 27 March 2018. The price of one share sold by the Shareholder was PLN 91.00. The private offering was addressed mainly at the U.S. institutional investors specializing in healthcare and biotechnology sectors who strengthened and diversified the Company's shareholding structure. The investors who purchased shares from the Shareholder and joined the Company's shareholding structure included, among others, the European Bank for Reconstruction and Development (EBRD) which purchased shares for PLN 61.4 million, and PFR Life Science sp. z o.o. (PFR Life Science), which purchased shares for PLN 38.3 million. Pursuant to framework agreements concluded with PFR Life Science and the EBRD, as long as PFR Life Science or the EBRD hold shares representing more than 1% of the Company's share capital, the EBRD, following consultations with PFR Life Science, will have the right to nominate a candidate to the Company's Supervisory Board, who shall meet the independence criteria stipulated in Annex II to the Commission Recommendation of 15 February 2005 on the role of non-executive or supervisory directors of listed companies and on the committees of the (supervisory) board. Pursuant to the framework agreement concluded with the EBRD, the Company undertook to follow good practices adopted by the EBRD in the scope of environmental and social policy and to comply with the policy for combating fraud. This information was published in Current Report No. 12/2018 on 23 March 2018.

On 22 March 2018, the Company received from the company contracted to analyses the results of the clinical trial with MabionCD20 in RA patients the confirmation that the status of the clinical trial results reported previously by the Company as "initial", following thorough data verification, was changed to "final". Thus the positive assessment of the clinical trial result did not change. The final versions of the report will be attached to the marketing authorization application (MAA). The positive trial results do not warrant the approval by the European Medicines Agency (EMA). This information was published in Current Report No. 13/2018 on 23 March 2018.

On 4 April 2018, the Company received information that the Company's application for co-funding of a project entitled "Expansion of the Research and Development Centre of Mabion S.A. – research on a new generation of medicines" submitted in the course of competition 2.1/2/2017 to Measure 2.1: Support for investments in R&D infrastructure of enterprises of the Smart Growth Operational Programme 2014-2020 has been selected for co-financing. The subject of the project is development of the company's R&D facilities by preparing the necessary infrastructure: the Research and Development Centre building and the purchase of research equipment for the purpose of research on innovative medicines. The designated Research and Development Centre will be used to develop the most cutting-edge generation of biotechnological medicines, – monoclonal antibodies – and prepare them for commercialization. The total cost of the Project is estimated at PLN 172.88 million and the recommended value of co-financing is equal to the amount specified in the application, i.e. PLN 63.25 million. By the date of publication of this report the co-financing agreement was not concluded. This information was published in Current Report No. 22/2018 on 4 April 2018.

On 18 April 2018 (event after the balance sheet date), the Company's Extraordinary General Meeting (EGM) adopted the resolution on an increase in the Company's share capital from PLN 1,180,000 to the amount of PLN 1,372,077.20 by means of issuing 1,920,772 P-series ordinary bearer shares with a par value PLN 0.10 each in the private placement according to Article 431 par. 2 point 1 of the KSH, addressed to Twiti Investments Ltd. The EGM decided to exclude the pre-emptive rights of the existing shareholders with respect to all P-series shares. The issue price of one P-series share was PLN 91 (total value of the issue: PLN 174.8 million). The Company's Management Board was authorized to apply for admission and introduction of the P-series shares and the rights to P-series shares into trading on the regulated market operated by Giełda Papierów Wartościowych S.A. and to conclude with Krajowy Depozyt Papierów Wartościowych S.A. (Central Securities Depository of Poland) the agreement on the registration in the securities depository of P-series shares as well as to take all and any further necessary measures for their dematerialisation. This information was published in Current Report No. 23/2018 on 18 April 2018.

On 23 April 2018 (event after the balance sheet date), the Company addressed to Twiti Investments Ltd. an offer to subscribe to the Company's 1,920,772 P-series ordinary bearer shares in the private placement according to Article 431 par. 2 point 1

of the KSH. The Shareholder accepted the offer to subscribe to P-series shares and on 23 April 2018 the P-series Share Subscription Agreement was concluded, under which the Shareholder subscribed to the Company's 1,920,772 P-series ordinary bearer shares with PLN 0.10 par value per share at the issue price of PLN 91.00 per share (total sale price of P-series shares equaled PLN 174.8 million). The total issue price for P-series shares was paid by the Shareholder in cash on 23 April 2018. The Company intends to use funds obtained from the P-series share issue among others for the expansion of the Research and Development Centre in Konstantynów Łódzki, covering the costs and expenses in connection with the development and commercialization of Mabion CD20, and repayment of loans from and other liabilities towards financial institutions. Information on the Shareholder's subscribing to P-series shares was published in Current Report No. 26/2018 on 23 April 2018.

On 25 May 2018 (event after the balance sheet date), the Company received from the company contracted to analyses the results in the scope of patients' response to treatment non-Hodgkin's lymphomas (NHL) the confirmation that the status of the clinical trial results reported in the previous announcements as "initial", following thorough data verification, was changed to "final".

Thus the positive assessment of the clinical trial result remains unchanged. The final versions of the reports will be enclosed to the marketing authorization application (MAA). The positive trial results do not warrant the product approval by the European Medicines Agency (EMA). This information was published in Current Report No. 35/2018 on 25 May 2018.

2.3 Indication of factors and events, including those of atypical nature, with a significant impact on the condensed financial statements

In the first quarter of 2017 there were no factors or events other than those indicated in other items of the report, including those of atypical nature, with a significant impact on the Company's condensed financial statements

2.4 Position of the Management Board concerning the possibility of meeting the previously published forecasts of results

The Company's Management Board took a decision to cancel the financial forecasts published in 2010 (prepared in connection with applying for admitting I-Series shares to trading in an alternative trading system) and to resign from publishing forecast financial results.

2.5 Structure of share capital

As at 31 March 2018, the Company's share capital amounted to PLN 1,180,000 and consisted of 11,800,000 shares with a par value of PLN 0.10 each, including:

- » 450,000 A-series registered preferred shares;
- » 450,000 B-series registered preferred shares;
- » 450,000 C-series registered preferred shares;
- » 450,000 D-series ordinary bearer shares;
- » 100,000 E-series registered preferred shares;
- » 100,000 F-series registered preferred shares;
- » 20,000 G-series registered preferred shares;
- » 2,980,000 H-series ordinary bearer shares;
- » 1,900,000 I-series ordinary bearer shares;
- » 2,600,000 J-series ordinary bearer shares;
- » 790,000 K-series ordinary bearer shares;
- » 510,000 L-series ordinary bearer shares;
- » 360,000 M-series ordinary bearer shares;
- » 340,000 N-series ordinary bearer shares;
- » 300,000 O-series ordinary bearer shares.

The A-, B-, C-, E-, F- and G-series shares are multiple-vote shares, giving the holder two votes at the General Meeting. The total number of votes resulting from all issues amounts to 13,070,000 votes.

On 30 April 2018 the District Court for Łódź-Śródmieście in Łódź, 20th Department of the National Court Register, registered the increase in the Company's share capital and the repeal of the provisions of the Articles of Associations relating to target capital.

The Company's share capital was increased from PLN 1,180,000.00 to PLN 1,372,077.20 in the result of issuing 1,920,772 P-series ordinary bearer shares with a par value of PLN 0.10 each.

Following the registration of the aforementioned change and as at the date of publication of this report the Company's share capital is PLN 1,372,077.20 and consists of 13,720,772 shares with a par value of PLN 0.10 each, including:

- » 450,000 A-series registered preferred shares;
- » 450,000 B-series registered preferred shares;
- » 450,000 C-series registered preferred shares;
- » 450,000 D-series ordinary bearer shares;
- » 100,000 E-series registered preferred shares;
- » 100,000 F-series registered preferred shares;
- » 20,000 G-series registered preferred shares;
- » 2,980,000 H-series ordinary bearer shares;
- » 1,900,000 I-series ordinary bearer shares;
- » 2,600,000 J-series ordinary bearer shares;
- » 790,000 K-series ordinary bearer shares;
- » 510,000 L-series ordinary bearer shares;
- » 360,000 M-series ordinary bearer shares;
- » 340,000 N-series ordinary bearer shares;
- » 300,000 O-series ordinary bearer shares;
- » 1,920,772 P-series ordinary bearer shares.

The A-, B-, C-, E-, F- and G-series shares are multiple-vote shares, giving the holder two votes at the General Meeting.

Following the registration of the increase in share capital the total number of votes resulting from all the issued shares is 15,290,772.

On 18 May 2018, the Company's Management Board, in connection with the request by the shareholder Twiti Investments Limited, submitted pursuant to Article 334 par. 2 of the Code of Commercial Companies and Partnerships, passed a resolution, in accordance with the submitted request, on the conversion of 514,773 P-series ordinary bearer shares into ordinary registered shares and on the issue of a global certificate of 514,773 ordinary registered shares numbered 1 to 514,773 as well as on depositing the global certificate of shares with the Company.

The shares being subject to conversion represent 3.75% of the share capital and 3.37% of the total number of votes in the Company. The P-series shares are not preferred shares. The remaining 1,405,999 P-series shares remain ordinary bearer shares.

The amount of the share capital and the total number of votes in the Company remained unchanged: the Company's share capital is PLN 1,372,077.20 and consists of 13,720,772 shares with a par value of PLN 0.10 each, and the total number of votes resulting from all the issued shares is 15,290,772.

2.6 Shareholding structure

According to the Management Board's knowledge, as at the date of submission of the report for the first quarter of 2018 (30 May 2018), the following shareholders hold at least 5% On 30 April of the total votes at the Company's General Meeting of Shareholders:

No.	Shareholder	Number of shares	Number of votes	% of share capital	% of votes held
1.	Twiti Investments Limited	2,520,072	3,114,372	18.37%	20.37%
2.	Maciej Wieczorek indirectly, including via*:	1,624,876	2,117,726	11.84%	13.85%
	Glatton Sp. z o.o.	1,004,526	1,004,526	7.32%	6.57%
	Celon Pharma S.A.	620,350	1,113,200	4.52%	7.28%
3.	Polfarmex S.A.	1,437,983	1,920,833	10.48%	12.56%
4.	Funds managed by Generali PTE S.A.	1,490,545	1,490,545	10.86%	9.75%
5.	Funds managed by Nationale Nederlanden PTE S.A.	912,390	912,390	6.65%	5.97%
6.	Funds managed by Investors TFI S.A.	794,566	794,566	5.79%	5.20%
8.	Other shareholders	4,940,340	4,940,340	36.01%	32.31%
	TOTAL	13,720,772	15,290,772	100%	100%

* Mr Maciej Wieczorek holds 100% in the share capital of Glatton Sp. z o.o. and indirectly, via Glatton Sp. z o.o., 66.67% in the share capital of Celon Pharma S.A. as well as 75% of the total number of votes in Celon Pharma S.A.

According to the knowledge of the Management Board, as at the date of publication of the previous report, i.e. the annual report for the year 2017 published on 26 April 2018, the following shareholders held at least 5% of the total votes at the Company's General Meeting of Shareholders (P-series share issue excluded as it was not registered with the NCR as at the publication of the annual report):

No.	Shareholder	Number of shares	Number of votes	% of share capital	% of votes held
1.	Maciej Wieczorek indirectly, including via*:	1,624,876	2,117,726	13.77%	15.84%
	Glatton Sp. z o.o.	1,004,526	1,004,526	8.51%	7.51%
	Celon Pharma S.A.	620,350	1,113,200	5.26%	8.33%
2.	Polfarmex S.A.	1,437,983	1,920,833	12.19%	14.37%
3.	Funds managed by Generali PTE S.A.	1,396,035	1,396,035	11.83%	10.44%
4.	Funds managed by Nationale Nederlanden PTE S.A.	912,390	912,390	7.73%	6.82%
5.	Funds managed by Investors TFI S.A.	794,566	794,566	6.73%	5.94%

No.	Shareholder	Number of shares	Number of votes	% of share capital	% of votes held
6.	European Bank for Reconstruction and Development	675,000	675,000	5.72%	5.05%
7.	Twiti Investments Limited	599,300	1,193,600	5.08%	8.93%
8.	Other shareholders	4,359,850	4,359,850	36.95%	32.61%
	TOTAL	11,800,000	13,370,000	100%	100%

* *Mr Maciej Wieczorek holds 100% in the share capital of Glatton Sp. z o.o. and indirectly, via Glatton Sp. z o.o., 66.67% in the share capital of Celon Pharma S.A. as well as 75% of the total number of votes in Celon Pharma S.A.*

2.7 The Company's bodies

2.7.1 Management Board

In the reporting period and until the date of submitting this report the composition of the Company's Management Board has not changed and as at 30 May 2018 it consists of three members:

- » Artur Chabowski - President of the Management Board,
- » Sławomir Jaros - Member of the Management Board,
- » Jarosław Walczak - Member of the Management Board.

2.7.2 Supervisory Board

In the reporting period and until the date of submitting this report the composition of the Company's Supervisory Board has not changed and as at 30 May 2018 it consists of eight members:

- » Robert Aleksandrowicz – Chairman of the Supervisory Board,
- » Maciej Wieczorek – Deputy Chairman of the Supervisory Board,
- » Grzegorz Stefański – Independent Member of the Supervisory Board,
- » Tadeusz Pietrucha – Independent Member of the Supervisory Board,
- » Jacek Piotr Nowak – Member of the Supervisory Board,
- » David John James – Independent Member of the Supervisory Board,
- » Artur Olech – Independent Member of the Supervisory Board,
- » Robert Koński – Independent Member of the Supervisory Board.

2.8 Shares held by managers and supervisors

	Shares held as at the date of submission of the report for the first quarter of 2018 (30 May 2018)
Management Board	
Artur Chabowski	indirectly, via FL Real Investments Holding Limited based in Nicosia (Cyprus), in which Artur Chabowski holds 100% of the share capital, holds the total of 24,034 shares in the Company with a par value of PLN 0.10 each, accounting for 0.18 % of the Company share capital and 0.16% votes at the General Meeting,

	Shares held as at the date of submission of the report for the first quarter of 2018 (30 May 2018)
Supervisory Board	
Robert Aleksandrowicz	directly holds 151,594 ordinary bearer shares with a par value of PLN 0.10 each, accounting for 1.10% of the Company share capital and 0.99% votes at the General Meeting;
	indirectly, via Twiti Investments Limited based in Nicosia (Cyprus), in which Robert Aleksandrowicz holds 50% of the share capital and 50% of votes at the general meeting of that company, is a shareholder in Mabion and holds 2,520,072 shares in the Company with a par value of PLN 0.10 each, accounting for 18.37% of the Company's share capital and 20.37% votes at the General Meeting.
Maciej Wiczorek	indirectly, via Glatton Sp. z o.o. (in which he holds 100% of the share capital) and Celon Pharma S.A. (in which he holds, indirectly, via Glatton Sp. z o.o. 66.67% of the share capital) holds the total of 1,624,876 shares in the Company with a par value of PLN 0.10 each, accounting for 11.84% of the Company's share capital and 13.85% votes at the General Meeting.

	Shares held as at the date of submission of the annual report for the year 2017 (26 April 2018)
Management Board	
Artur Chabowski	indirectly, via FL Real Investments Holding Limited based in Nicosia (Cyprus), in which Artur Chabowski holds 100% of the share capital, held the total of 24,034 shares in the Company with a par value of PLN 0.10 each, accounting for 0.2 % of the Company share capital and 0.18% votes at the General Meeting.
Supervisory Board	
Robert Aleksandrowicz	directly held 151,594 ordinary bearer shares with a par value of PLN 0.10 each, accounting for 1.28% of the Company's share capital and 1.13% votes at the General Meeting;
	indirectly, via Twiti Investments Limited based in Nicosia (Cyprus), in which Robert Aleksandrowicz holds 50% of the share capital and 50% of votes at the general meeting of that company, and which is a shareholder in Mabion, held the total of 599,300 shares in the Company with a par value of PLN 0.10 each, accounting for 5.08 % of the Company's share capital and 8.93 % votes at the General Meeting. Furthermore, on 23 April 2018 Twiti Investments Limited acquired 1,920,772 of the O-series shares in Mabion S.A. with a par value of PLN 0.10 each. By the date of publication of this report the increase in the Company's share capital was not registered with the National Court Register.
Maciej Wiczorek	indirectly, via Glatton Sp. z o.o. (in which he holds 100% of the share capital) and Celon Pharma S.A. (in which he holds, indirectly, via Glatton Sp. z o.o. 66.67% of the share capital) held the total of 1,624,876 shares in the Company with a par value of PLN 0.10 each, accounting for 13.77% of the Company's share capital and 15.84% votes at the General Meeting.

As at the date of publication of this Report, i.e. as at 30 May 2018, other managers and supervisors don't hold any shares in the Company and this status has not changed in the period from the publication of the annual report for the year 2017. Members of the Management Board and the Supervisory Board of Mabion S.A. have no rights to the Company's shares.

2.9 Litigation pending before the court, the appropriate arbitration body or the public administration body

In the first quarter of 2018, no material court, arbitration or administrative proceedings were in progress before a court, a body competent for arbitration proceedings or a public administration body.

2.10 Transactions with related parties

In the first quarter of 2018, the Company did not enter into transactions with related entities on terms other than arm's length.

2.11 Sureties and guaranties granted

In the first quarter of 2018, the Company did not grant any sureties for loans or any guaranties jointly to one entity or subsidiary of that entity, where the total value of the existing sureties or guaranties is significant.

2.12 Factors which will have an impact on the achieved financial results in the perspective of at least the following quarter

In future reporting periods revenues will be primarily derived from:

- » expected distribution fees for MabionCD20 medicine (milestone payments),
- » aid from EU funds,
- » loans provided by banks,
- » funds obtained under operating or finance leases,
- » future share issues,
- » performance of contracts for the provision of research and development services,
- » borrowings from shareholders.

The level of revenues may be influenced by potential delays in conducted negotiations or unexpected deviations from the schedules of agreements already signed

2.13 Other information material to the assessment of the Company's position

In the first quarter of 2018 there were no one-off events. The Company's activity was comparable to that in the earlier periods.

There is no other information which is material to the assessment of the human resources, asset and financial position of Mabion S.A., its results and respective changes, and information material to assessing its ability to discharge its liabilities.

3 Contact details

Company name:	Mabion Spółka Akcyjna
Registered office:	Konstantynów Łódzki
Address:	ul. gen. Mariana Langiewicza 60 95-050 Konstantynów Łódzki
Telecommunications numbers:	tel. +48 42 207 78 90 faks +48 42 203 27 03
e-mail address:	info@mabion.eu
Website address:	www.mabion.eu

The Company's Management Board

Konstantynów Łódzki, 30 May 2018




Artur Chabowski

President of the Management Board



Sławomir Jaros

Member of the Management Board



Jarosław Walczak

Member of the Management Board

